1-2 of 2
Heiner Zimmermann, MD
Close
Sort by
Journal Articles

Burden of Hospitalizations Due to Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV + PTLD) in Patients Who Failed First Line Rituximab or Rituximab Plus Chemotherapy Following Solid Organ Transplant (Post-SOT): A Retrospective Chart Review Study of German PTLD Registry

Heiner Zimmermann, MD, Hairong Xu, MD PhD, Arie Barlev, PharmD, Yang Zhang, PhD, Dhanalakshmi Thirumalai, Crystal Watson, MS, Ralf Ulrich Trappe, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 65.
https://doi.org/10.1182/blood-2019-124583
Published: 2019
Journal Articles

Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients

Ralf Ulrich Trappe, MD, Daan Dierickx, MDPhD, Heiner Zimmermann, MD MB BChir, Franck Morschhauser, MD, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Jan M Zaucha, MD PhD, Martin H. Dreyling, MD PhD, Ulrich Dührsen, MD, Petra Reinke, MD, Gregor Verhoef, MD PhD, Marion Subklewe, MD, Andreas Hüttmann, MD, Thomas Tousseyn, MDPhD, Gilles A. Salles, MD PhD, Volker Kliem, MD, Corrado Tarella, Eric W Van Den Neste, MD PhD, Ingeborg A Hauser, MD, Olivier Gheysens, MD, Iannis Anagnostopoulos, MD, Veronique Leblond, MD PhD, Hanno Riess, MD, Sylvain Choquet, MD
Journal: Blood
Blood (2015) 126 (23): 816.
https://doi.org/10.1182/blood.V126.23.816.816
Published: 2015